Psoriatic Arthritis

The US FDA approved upadacitinib (15 mg daily) for the treatment of adults with active psoriatic arthritis with inadequate response to at least 1 TNF blocker.

Ana-Maria Orbai, MD, MHS, comments on the safety and efficacy of TNF-alpha inhibitors for the management of psoriatic arthritis and Anthony M. Turkiewicz, MD, reviews the phase 3 FUTURE trials.

Sheetal Desai, MD, reviews the MOAs of currently available biologics for the management of psoriatic arthritis.

Leonard H. Calabrese, DO, shares insight on goals of therapy and factors that guide treatment selection for patients with psoriatic arthritis.

Previous studies examining whether inflammatory disease was associated with an increased risk of Alzheimer's disease yielded mixed results.

Guselkumab is the first and only selective interleukin inhibitor therapy in the US that's approved for both moderate-severe plaque psoriasis and active psoriatic arthritis regardless of prior TNFi exposure.

Philip Mease, MD, explains the recent Phase 3 data from the DISCOVER-1 and DISCOVER-2 clinical trials which demonstrated guselkumab inhibited radiographic progression, and improved symptoms and pain in patients with active psoriatic arthritis (PsA).

A correlation between disease activity and overall hand functionality was discovered in patients with psoriatic arthritis.

Anthony M. Turkiewicz, MD, leads the discussion on diagnosing psoriatic arthritis (PsA), including differentiating PsA from axial spondyloarthritis, and comments on the role of CASPAR criteria in clinical practice.

Sheetal Desai, MD, leads the discussion on the typical presentation of psoriatic arthritis, common comorbidities associated with the disease, and the importance of an early and accurate diagnosis.

Louis Bessette, MD, MSc, explains the impact of early pain improvement on patient-reported outcomes in patients with psoriatic arthritis.

Ana-Maria Orbai, MD, FACR, MHS, explains how guselkumab improved PROMIS-29 scores in patients with psoriatic arthritis.

Soumya Chakravarty, MD, PhD, discusses the unmet patient needs in immune-mediated diseases and Janssen’s role in scientific innovation that allows patients to live their lives unburdened by disease.

Leonard H. Calabrese, DO; Sheetal Desai, MD; and Ana-Maria Orbai, MD, MHS, discuss the impact of psoriatic arthritis on a patient’s quality of life [QoL] and describe tools for measuring QoL.

Leonard H. Calabrese, DO, provides insight on the pathophysiology of psoriatic arthritis [PsA].

The biologic has shown promise in the management of both plaque psoriasis and psoriatic arthritis.

Though Dr. Khattri felt the diagnosis of psoriatic arthritis had been “stagnant”, the inclusion of biologic therapies and more has been a welcomed change.

Continual improvement was shown in patient-reported pain levels when treated with guselkumab compared with placebo.

Hermine Brunner, MD, MSc, MBA, discusses secukinumab treatment in patients with enthesitis-related arthritis and juvenile psoriatic arthritis.

Investigators observed stark contrasts in COVID-19 mRNA vaccination response among inflammatory rheumatic disease patients and the general population.

An assessment of a rheumatic disease cohort shows Spike protein antibody response is significantly decreased in vaccinated patients, and may vary by treatment.

A study presented at ACR 2021 found that CBD had no significant effect on pain intensity in patients with hand osteoarthritis or psoriatic arthritis.

An assessment of data from the DISCOVER and VOYAGE trials show the IL-23 inhibitor provides similar safety profiles in patients with either psoriatic disease.

With the popularity of CBD growing in Denmark, Jonathan Vela, MD, examined the effectiveness of CBD treatment on hand osteoarthritis and psoriatic arthritis.

The oral selective inhibitor showed significant benefit versus placebo at 2 different doses in the phase 2b trial.